Recurrence of a high‐titre factor VIII inhibitor in a haemophilia A patient on emicizumab prophylaxis-Reference-Cited by-同舟云学术

Recurrence of a high‐titre factor VIII inhibitor in a haemophilia A patient on emicizumab prophylaxis

Published:2021-04-18 Issue:4 Volume:27 Page:
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Doshi Bhavya S.¹²^ORCID,Witmer Char M.¹²

Affiliation:

1. Division of Hematology The Children's Hospital of Philadelphia Philadelphia PA USA

2. Department of Pediatrics University of Pennsylvania Philadelphia PA USA

Publisher

Wiley

Subject

Genetics(clinical),Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hae.14311

Reference10 articles.

1. The principal results of the International Immune Tolerance Study: a randomized dose comparison

2. Emicizumab Prophylaxis in Hemophilia A with Inhibitors

3. Real‐world use of emicizumab in patients with haemophilia A: Bleeding outcomes and surgical procedures

4. Factor VIII inhibitor testing using a validated chromogenic Bethesda assay in HAVEN 1 (BH29884), a Phase 3 trial of emicizumab in persons with hemophilia A with Inhibitors;Adamkiewicz JJ;Res Pract Thromb Haemost,2017

5. Emicizumab in tolerized patients with hemophilia A with inhibitors: A single‐institution pediatric cohort assessing inhibitor status

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emicizumab is well tolerated and effective in people with congenital hemophilia A regardless of age, severity of disease, or inhibitor status: a scoping review;Research and Practice in Thrombosis and Haemostasis;2024-05

2. Efficacy, safety and cost of emicizumab prophylaxis in haemophilia A patients with inhibitors: A nationwide observational study in Taiwan;Haemophilia;2023-10-11

3. Longitudinal dynamic changes in factor VIII inhibitor titers in patients with hemophilia A and inhibitors receiving emicizumab prophylaxis;International Journal of Hematology;2023-10-06

4. Factor VIII inhibitors in hemophilia A treated with emicizumab: longitudinal follow-up of outcomes;Research and Practice in Thrombosis and Haemostasis;2023-05

5. Real-world experience of emicizumab prophylaxis in young children with hemophilia A: retrospective data from China;Frontiers in Pediatrics;2022-10-19